These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 4682237)
21. Factor VIII products and inhibitors in severe hemophilia A. Iorio A; Skinner MW; Makris M N Engl J Med; 2013 Apr; 368(15):1456. PubMed ID: 23574132 [No Abstract] [Full Text] [Related]
22. Factor VIII products and inhibitors in severe hemophilia A. van den Berg HM; Gouw SC; van der Bom JG N Engl J Med; 2013 Apr; 368(15):1457. PubMed ID: 23574131 [No Abstract] [Full Text] [Related]
23. Lack of response to commercial factor VIII concentrate in hemophilia A. Rodgers GM; Ford MH Am J Hematol; 1991 Aug; 37(4):288. PubMed ID: 1907098 [No Abstract] [Full Text] [Related]
24. Factor VIII concentrate available for treatment of classical hemophilia. Jewett WR Ann N Y Acad Sci; 1975 Jan; 240():188-90. PubMed ID: 1053863 [No Abstract] [Full Text] [Related]
25. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Hsu HC; Chen YF; Ho CH Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180 [TBL] [Abstract][Full Text] [Related]
26. Porcine factor VIII therapy in patients with factor VIII inhibitors. Hay C; Lozier JN Adv Exp Med Biol; 1995; 386():143-51. PubMed ID: 8851022 [No Abstract] [Full Text] [Related]
28. An in vivo assessment of factor VIII concentrates. Rock G; Tittley P; Fuller V JAMA; 1985 Aug; 254(6):777-80. PubMed ID: 3925170 [TBL] [Abstract][Full Text] [Related]
29. Transient factor VIII inhibitor and treatment with monoclonal-antibody-purified factor VIII. Montoro JB; Rodríguez S; Altisent C; Tusell JM Lancet; 1991 May; 337(8751):1222. PubMed ID: 1673757 [No Abstract] [Full Text] [Related]
30. Letter: Hemophilia: cyclophosphamide and factor VIII concentrate. Stein RS Ann Intern Med; 1974 Nov; 81(5):706-7. PubMed ID: 4419955 [No Abstract] [Full Text] [Related]
31. Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group. Walker I; Poon MC Lancet; 1992 Jan; 339(8784):61-2. PubMed ID: 1345984 [No Abstract] [Full Text] [Related]
32. Choice of replacement therapy for hemophilia-cryoprecipitate issues: a rebuttal. Farrugia A; Giangrande P J Thromb Haemost; 2004 Jun; 2(6):1022-3. PubMed ID: 15140151 [No Abstract] [Full Text] [Related]
33. [Substitution therapy with factor 8 and factor IX preparations]. Landbeck G Hamatol Bluttransfus; 1968; 5():29-42. PubMed ID: 5729465 [No Abstract] [Full Text] [Related]
34. [Factor VIII preparation]. Mikami S Nihon Rinsho; 1981; 39(12):3680-7. PubMed ID: 6803033 [No Abstract] [Full Text] [Related]
35. The therapy of classic hemophilia (factor VIII deficiency): past, present and future. Breckenridge RT Am J Med Sci; 1972 Apr; 263(4):275-80. PubMed ID: 5031994 [No Abstract] [Full Text] [Related]
36. Analysis of contaminants in factor VIII preparations administered to patients with hemophilia. Rock GA; Farrah G; Rozon G; Smiley RK; Cole R; Villeneuve D; Tittley P Can Med Assoc J; 1983 Feb; 128(4):403-8. PubMed ID: 6401585 [TBL] [Abstract][Full Text] [Related]
37. [Transmission of the human immunodeficiency virus by a dry heat-treated Factor VIII concentrate?]. Weisser J Klin Padiatr; 1988; 200(5):375-9. PubMed ID: 3141670 [TBL] [Abstract][Full Text] [Related]
38. The current approach to hemophilia. Morrison CJ J Maine Med Assoc; 1974 Sep; 65(9):205-6. PubMed ID: 4416140 [No Abstract] [Full Text] [Related]